Kim Seung-Hyun, Hur Gyu-Young, Choi Jeong-Hee, Park Hae-Sim
Ajou University School of Medicine, Department of Allergy & Rheumatology, San-5, WonchonDong, YoungtongGu, Suwon, Korea.
Pharmacogenomics. 2008 Jan;9(1):85-91. doi: 10.2217/14622416.9.1.85.
Leukotriene overproduction is the major characteristic of aspirin-intolerant asthma (AIA). Most studies examining the molecular genetic mechanisms of AIA have focused on leukotriene-related genes, including ALOX5, LTC4S, TXA2R and prostanoid-receptor genes. One study suggested that the human leukocyte antigen (HLA) allele DPB10301 may be a genetic marker for the AIA phenotype in European and Asian populations, and HLA-DPB10301 has been suggested as a useful genetic marker for predicting more favorable responders to leukotriene-receptor antagonists for long-term management of AIA. Although several reports have indicated possible associations between genetic polymorphisms and variable responses to leukotriene modifiers in nonaspirin sensitive asthmatic patients, few have suggested relationships between such genetic polymorphisms and variable responses to asthma drugs in AIA patients.
白三烯过度产生是阿司匹林不耐受性哮喘（AIA）的主要特征。大多数研究AIA分子遗传机制的研究都集中在白三烯相关基因上，包括5-脂氧合酶（ALOX5）、白三烯C4合成酶（LTC4S）、血栓素A2受体（TXA2R）和前列腺素受体基因。一项研究表明，人类白细胞抗原（HLA）等位基因DPB10301可能是欧洲和亚洲人群中AIA表型的遗传标志物，并且HLA-DPB10301已被认为是一种有用的遗传标志物，用于预测白三烯受体拮抗剂对AIA长期管理的更有利反应者。尽管有几份报告指出非阿司匹林敏感哮喘患者的基因多态性与对白三烯调节剂的可变反应之间可能存在关联，但很少有研究表明此类基因多态性与AIA患者对哮喘药物的可变反应之间的关系。
